SFRP2 Gene Methylation as a Breast Cancer Marker
Author Information
Author(s): Jürgen Veeck, Erik Noetzel, Nuran Bektas, Edgar Jost, Arndt Hartmann, Ruth Knüchel, Edgar Dahl
Primary Institution: Molecular Oncology Group, Institute of Pathology, University Hospital of the RWTH Aachen
Hypothesis
Is SFRP2 promoter methylation implicated in human breast cancer and can it serve as a tumor biomarker?
Conclusion
SFRP2 gene methylation is a frequent alteration in human breast cancer, potentially serving as a tumor-specific biomarker.
Supporting Evidence
- SFRP2 promoter methylation was detected in 165 out of 199 primary breast carcinomas (83%).
- Loss of SFRP2 protein expression was observed in 74% of invasive breast carcinoma specimens.
- SFRP2 methylation was not found in matched normal breast tissues.
Takeaway
The SFRP2 gene is often turned off in breast cancer due to a process called methylation, which can help doctors find the disease earlier.
Methodology
The study analyzed SFRP2 mRNA expression and promoter methylation in breast cancer cell lines and primary tumors using various PCR techniques.
Potential Biases
Potential bias due to the selection of cases based on tissue availability.
Limitations
The study did not stratify cases for known preoperative or pathological prognostic factors.
Participant Demographics
Median patient age was 67 years for matched tumor samples and 57 years for unmatched breast carcinomas.
Statistical Information
P-Value
P < 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website